





Fax Completed Form To 1.833.404.2392

Prescriber Help Desk 1.833.587.2012

Online

covermymeds.com/main/ prior-authorization-forms/

Request for Prior Authorization

Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB			
Patient address					
Provider NPI	Prescriber name	Phone			
Prescriber address		Fax			
Pharmacy name	Address	Phone			
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax	NDC 			

Prior authorization is required for oral gonadotropin-releasing hormone (GnRH) antagonists. Payment for non-preferred oral GnRH antagonists may be considered only for cases in which there is documentation of a previous trial and therapy failure with the preferred agent. Payment will be considered for patients when the following is met:

- 1) Pregnancy has been ruled out; and
- 2) Patient does not have osteoporosis; and
- 3) Request adheres to all FDA approved labeling for requested drug, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
- 4) Requests for elagolix (Orilissa) or relugolix, estradiol, norethindrone acetate (Myfembree) will be considered under the following conditions:
 - a. Patient has a diagnosis of moderate to severe pain associated with endometriosis; and
 - b. Patient has documentation of a previous trial and therapy failure with at least one preferred oral NSAID and at least one preferred 3-month course of a continuous hormonal contraceptive taken concurrently; and
 - c. Patient has documentation of a previous trial and therapy failure with a preferred GnRH agonist.
 - d. Initial requests will be considered for 3 months. Additional requests will be considered upon documentation of improvement of symptoms; and
 - e. Requests will be considered based on drug, dose, and length of therapy:
 - i. Orilissa-maximum duration of therapy of 24 months for the 150mg dose and 6 months for the 200mg dose; or
 - ii. Myfembree- maximum duration of therapy of 24 months; or
- 5) Requests for elagolix, estradiol, and norethindrone acetate; elagolix (Oriahnn) or relugolix, estradiol, norethindrone acetate (Myfembree) will be considered under the following conditions:
 - a. Patient is premenopausal; and
 - b. Patient has a diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids); and
 - c. Patient has documentation of a previous trial and therapy failure with at least one preferred 3-month course of a continuous hormonal contraceptive; and
 - d. Patient has documentation of a previous trial and therapy failure with tranexamic acid.
 - e. Initial requests will be considered for 6 months. Additional requests will be considered upon documentation of improvement in symptoms.
 - f. Requests will be considered for a maximum duration of therapy of 24 months.

(Rev. 1/24) Page 1 of 3



Preferred





Request for Prior Authorization Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Fax Completed Form To 1.833.404.2392 Prescriber Help Desk 1.833.587.2012 Online covermymeds.com/main/

prior-authorization-forms/

☐ Myfembree ☐ Oriahnn	Orilissa			
Strength	Dosage Instruc	tions	Quantity	Days Supply
☐ Initial Requests:				
Has pregnancy been ruled out?	☐ Yes	☐ No	Date of pregnancy test:	
Does patient have osteoporosis?	☐ Yes	☐ No		
Does patient have severe hepatic	: impairment?	☐ Yes	☐ No	
Moderate to Severe Pain assTreatment Failures:Preferred Oral NSAID Trial:			•	·
Name/dose:				
Failure reason/medical contraindicati	on:			
Preferred Continuous Hormona Name/dose: Failure reason/medical contraindicati	·			
Preferred GnRH Agonist Trial: Name/dose:			Trial dates:	
Failure reason/medical contraindicati	on:			

(Rev. 1/24) Page 2 of 3







Request for Prior Authorization Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Fax Completed Form To 1.833.404.2392 Prescriber Help Desk 1.833.587.2012 Online covermymeds.com/main/ prior-authorization-forms/

☐ Heavy menstrual bleeding asso	ciated with uterin	e leiomyomas ((fibroids) (Oriahnn & Myfen	nbree)	
Is patient premenopausal?	☐ Yes ☐	No			
Treatment Failures:					
Preferred Continuous Hormonal C	Contraceptive Tria	l:			
Name/dose:			Trial dates:		
Failure reason/medical contraindication	:				
Tranexamic Acid Trial:					
Name/dose:		Tr	al dates:		
Failure reason/medical contraindication	:				
Reason for use of Non-Preferred d	Irug requiring prio	r approval:			
☐ Renewal Requests:					
Provide documentation of improvemen	t in symptoms:				
Treatment start date:					
Attach lab results and other docume	ntation as necessar	y.			
Prescriber signature (Must match prescriber	listed above.)		Date of submission		

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

(Rev. 1/24) Page 3 of 3